From Medinet
Jump to: navigation, search

What is MediNet

MediNet is structured as a Networking Activity within the EU-funded (H2020) ENSAR-2, the programme that integrates the activities for European nuclear scientists who are performing research in three of these major subfields: Nuclear Structure, Nuclear Reactions and Applications of Nuclear Science. ENSAR-2 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 654002

MediNet Mission:Cancer ranges amongst the most severe challenges to modern society, rendering the development of effective tumour treatment of highest societal significance. Nuclear-Physics-related knowledge, technology and expertise are highly relevant to improve tumour diagnostics as well as therapy, thus contributing importantly to the advancement of public healthcare. Particle therapy has undergone major technological developments in the last two decades and has been shown to be effective especially for the treatment of tumours in the vicinity of sensitive organs at risk. The increasing importance of particle therapy manifests itself in the increasing number of proton and carbon ion therapy facilities worldwide, e.g. more than ten facilities are operational in Europe, while a similar number is under construction or in the planning stage. Noteworthy in this context is the interest expressed by the US Department of Energy (DOE) and the National Cancer Institute (NCI) to learn from the experience and perspectives of modern particle therapy technologies in Europe . At the same time, also the more widespread forms of radiotherapy, such as those based on intensity modulated photon beams (IMRT), are continuously being optimized. The optimization of radiation therapy in general and particle therapy in particular requires research on a variety of topics such as beam delivery optimization, in-vivo monitoring of the delivered dose, dosimetry, radiobiology and radiation quality. Expertise in nuclear techniques for the detection and characterization of charged particles and photons is crucial to each of these objectives. Large efforts are therefore devoted to the development of innovative detector technologies and modelling in several European research groups, focusing on both clinical and pre-clinical applications of particle therapy. Under the common topical umbrella of nuclear tools applied to the medical environment, two distinct but complementary pillars (Task1 and Task 2) are jointly pursued within the MediNet NA